Skip to main content

Advertisement

Table 3 Mean change of eGFR during ERT in 30 male and 27 female patients per CKD stage

From: Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain

CKD stage at start of ERT Males Females
  N eGFR change ± SE/year p-value N eGFR change ± SE/year p-value
at increased risk for CKD **(=GFR > 60, no microalbuminuria or proteinuria) 7 -2.5 ± 0.4* <0.001 6 -1.0 ± 0.5* 0.05
CKD1 (=GFR > 90 and microalbuminuria) 10 -4.5 ± 0.4* <0.001 7 -1.3 ± 0.7 0.07
CKD2 (=GFR 60-90 and microalbuminuria) 4 -2.1 ± 0.3 <0.001 10 -0.3 ± 0.3 0.25
CKD3 (=GFR30-60) 6 -4.1 ± 0.2 <0.001 3 -1.4 ± 0.5 0.015
CKD4(=GFR 15-30) 3 -2.0 ± 0.2 <0.001 1 -3.5 ± 0.3 -
CKD5 (=GFR < 15) 0    0   
  1. M = male, F = female. * eGFR change without hyperfiltration (GFR > 135 ml/min/1.73 m2) in males: at increased risk for CKD** (5M): -2.2 ± 0.4 ml/min/1.73 m2 (p < 0.001), CKD 1 (7M) -3.4 ± 0.4 ml/min/1.73 m2 (p < 0.001) and in females: at increased risk for CKD** (5F): 0.9 ± 0.5 (p = 0.06). ** at increased risk for CKD according to CKD guidelines. The p-value indicates whether the change in renal function is significant.